Global Bulk Drugs Industry Report

Publication Date	August 2006
Publisher	Cygnus
Product Type	Report
Pages	98
ISBN Number	not applicable
Product Code	CYG00012

Price

£550.00
approximately: $817 | €647

OTHER ($817 | €647)

Order above formats by FAX

Summary

Introduction

The global bulk drugs market, worth an estimated US$77.33 billion in 2005, grew at a compounded annual growth rate (CAGR) of 9.2% in the last five years. The contract manufacturing of bulk drugs and prescription drugs touched an estimated US$28.97 billion in 2005, and is expected to rise to US$43.34 billion at a CAGR of 10.6% by the end of 2009.

Key Findings & Highlights

Bulk drug industry is undergoing radical change - The thinning research pipelines, the growing pricing pressures and increasing importance of generics are leading to far-reaching changes in the bulk drug industry.

The worldwide production of bulk drugs - active substances in drugs that perform the desired therapeutic actions, totalled US$77.33 billion in 2005- and expected to touch US$84.4 billion in 2006.

The three segments - Branded Prescription Drugs, Over-the-Counter Drugs and Generic Prescription Drugs-account for a majority of global bulk drug consumption.

Reasons to Purchase

Gain a thorough understanding - of new product opportunities of non captive API manufacturers, industry estimates about the drugs which will go off-patent by 2010.

Estimates the production of bulk drugs industry and growth of the production volume over the last five years.

Reveals the top 10 bulk drugs as per the therapeutic class also about their share onto the global bulk drug industry. Also about the Cholesterol & Triglyceride Reducers drugs accounted for bulk drug Consumption

Content

1. Executive Summary
2. Highlights
3. Market Overview
- 3.1 Global pharmaceutical market
  - 3.1.1 Major markets
  - 3.1.2 Leading therapeutic classes
  - 3.1.3 Leading drugs
- 3.2 Global bulk drug market
  - 3.2.1 Market size
  - 3.2.2 Industry structure
  - 3.2.3 Major segments
  - 3.2.4 Top 10 Bulk Drugs -Therapeutic Class-wise
  - 3.2.5 Major bulk drugs
  - 3.2.6 Major markets3.2.7 Industry trends
4. Growth Drivers
- 4.1 Growth in the biotechnology sector
- 4.2 High growth of generics
- 4.3 Growth in CIS countries
- 4.4 A large number of additions to OTC segment
- 4.5 New regulation will boost growth of API's
- 4.6 New drug developments
- 4.7 Overall pharmaceutical growth
5. Issues And Challenges
- 5.1 Overcapacity
- 5.2 Competition on the cost front
- 5.3 Undifferentiated capabilities
- 5.4 Backward Integration of Research-based companies
- 5.5 Coping with changing disease profile
- 5.6 Varying regulatory requirements lead to additional costs
6. Regulatory Issues
- 6.1 Intellectual property rights
  - 6.1.1 General Agreement on Tariffs and Trade (GATT)
  - 6.1.2 Trade Related Aspects of Intellectual Property Rights (TRIPS)
  - 6.1.3 The Paris Convention (PCPIP)
  - 6.1.4 The Patent Co-operation Treaty (PCT)
- 6.2 Prolonging Patent Protection
  - 6.2.1 GATT & TRIPS
  - 6.2.2 The Waxman Hatch Act
- 6.3 Current Good Manufacturing Practices (cGMP)
  - 6.3.1 USA
  - 6.3.2 Europe
  - 6.3.3 Japan
  - 6.3.4 India
- 6.4 Drug Master Files
  - 6.4.1 USA
  - 6.4.2 Europe 6.4.3 Japan
- 6.5 Drug regulation in China
7. Major Players 7.1 Merck Kgaa
- - 7.1.1 Business profile
  - 7.1.2 Financial profile
  - 7.1.3 Key strategy
  - 7.1.4 Outlook
- 7.2 Teva Pharmaceutical Industries
  - 7.2.1 Business profile
  - 7.2.2 Financial profile
  - 7.2.3 Key strategies
  - 7.2.4 Outlook
- 7.3 Sandoz
  - 7.3.1 Business profile
  - 7.3.2 Financial profile
  - 7.3.3 Key strategy
  - 7.3.4 Outlook
- 7.4 Pliva
  - 7.4.1 Business profile
  - 7.4.2 Financial profile
  - 7.4.3 Key strategy
  - 7.4.4 Outlook
- 7.5 Watson Pharmaceuticals
  - 7.5.1 Business profile
  - 7.5.2 Financial profile
  - 7.5.3 Key strategy
  - 7.5.4 Outlook
- 7.6 Barr Pharmaceuticals Inc
  - 7.6.1 Business profile
  - 7.6.2 Financial profile
  - 7.6.3 Key strategy
  - 7.6.4 Outlook
- 7.7 Hexal Ag
  - 7.7.1 Business profile
  - 7.7.2 Key strategy
  - 7.7.3 Outlook
- 7.8 Mylan Laboratories Inc
  - 7.8.1 Business profile
  - 7.8.2 Financial Profile
  - 7.8.3 Key strategy
  - 7.8.4 Outlook
- 7.9 Andrx Corporation7.9.1 Business profile
  - 7.9.2 Financial profile
  - 7.9.3 Key strategy
  - 7.9.4 Outlook
- 7.10 Ratiopharm
  - 7.10.1 Business profile
  - 7.10.2 Key strategy
  - 7.10.3 Outlook
- 7.11 Ranbaxy Laboratories
  - 7.11.1 Business profile
  - 7.11.2 Financial profile
  - 7.11.3 Key strategy 7.11.4 Outlook 7.12 Stada Pharmaceuticals
  - 7.12.1 Business profile
  - 7.12.2 Financial profile
  - 7.12.3 Key strategy 7.12.4 Outlook
- 7.13 Actavis
  - 7.13.1 Business profile
  - 7.12.2 Financial profile
  - 7.13.2 Key strategy
  - 7.13.3 Outlook
- 7.14 Dr. Reddy's Laboratories Limited
  - 7.14.1 Business profile
  - 7.14.2 Financial profile
  - 7.14.3 Key strategy
  - 7.14.4 Outlook
- 7.15 Aurobindo Pharma Ltd
  - 7.15.1 Business profile
  - 7.15.2 Financial profile
  - 7.15.3 Key strategy
  - 7.15.4 Outlook
8. Critical Success Factors
- 8.1 Low-cost manufacturing skills
- 8.2 Striking strategic alliances
- 8.3 Growing experience with GMP compliance
- 8.4 Complex synthesis capabilities
- 8.5 Targeting right opportunities at right time
9. Future Outlook